Effect of aggressive diuresis in acute heart failure with reduced and preserved ejection fraction

Abstract Aims Heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF) had distinct haemodynamic characteristics in the setting of acute heart failure. The aim of our study is to evaluate the differential response to aggressive diuresis in HFrEF...

Full description

Bibliographic Details
Published in:	ESC Heart Failure
Main Authors:	Xin He, Bin Dong, Ruicong Xue, Jingjing Zhao, Zexuan Wu, Yuzhong Wu, Yuanyuan Zhou, Dexi Wu, Yugang Dong, Jiangui He, Chen Liu
Format:	Article
Language:	English
Published:	Wiley 2021-08-01
Subjects:	Acute heart failure Heart failure with reduced ejection fraction Heart failure with preserved ejection fraction Aggressive diuresis Loop diuretics
Online Access:	https://doi.org/10.1002/ehf2.13453

Similar Items

Diabetic microvascular complications predicts non‐heart failure with reduced ejection fraction in type 2 diabetes
by: Mayu Tochiya, et al.
Published: (2023-04-01)

Heart Failure With Mid-range Ejection Fraction: Every Coin Has Two Sides
by: Kaiyuan Zhu, et al.
Published: (2021-07-01)

Association of Depression and Anxiety with Cardiac Structural and Functional Characteristics in Heart Failure with Reduced and Mildly Reduced Ejection Fraction
by: Timea Magdolna Szabo, et al.
Published: (2023-03-01)

Clinical management of heart failure with improved ejection fraction: treatment and maintenance
by: XU Tianyun, et al.
Published: (2025-04-01)

Central and Obstructive Apneas in Heart Failure With Reduced, Mid-Range and Preserved Ejection Fraction
by: Chiara Borrelli, et al.
Published: (2019-09-01)

Eligibility of patients with heart failure with preserved ejection fraction for sacubitril/valsartan according to the PARAGON‐HF trial
by: Lars H. Lund, et al.
Published: (2022-02-01)

Sacubitril/valsartan in patients with mildly reduced or preserved ejection fraction and worsening heart failure: A review
by: Igor V. Zhirov, et al.
Published: (2023-11-01)

Association of ambient temperature and acute heart failure with preserved and reduced ejection fraction
by: Takahiro Jimba, et al.
Published: (2022-10-01)

Interpretation of the Essential Updates in 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure
by: Yifang GUO
Published: (2022-06-01)

Left Ventricular Ejection Fraction in Heart Failure: Crazy, Stupid Love—and Maybe, Redemption
by: Milton Packer
Published: (2024-04-01)

Understanding How Heart Metabolic Derangement Shows Differential Stage Specificity for Heart Failure with Preserved and Reduced Ejection Fraction
by: Federico Ferro, et al.
Published: (2022-07-01)

Vericiguat: The Fifth Harmony of Heart Failure with Reduced Ejection Fraction
by: Luigi Falco, et al.
Published: (2023-09-01)

Prevalence and Long‐Term Survival After Coronary Artery Bypass Grafting in Women and Men With Heart Failure and Preserved Versus Reduced Ejection Fraction
by: Louise Y. Sun, et al.
Published: (2018-06-01)

Elevating Expectations: Vericiguat in Heart Failure with Reduced Ejection Fraction
by: Pushpraj Patel, et al.
Published: (2024-12-01)

New possibilities in pharmacotherapy for the heart failure with reduced ejection fraction treatment in patients with recent deterioration
by: I. V. Gribkova
Published: (2024-03-01)

Epicardial adipose tissue volume and density are associated with heart failure with improved ejection fraction
by: Chen Die Yang, et al.
Published: (2024-08-01)

IL‐6 and hsCRP predict cardiovascular mortality in patients with heart failure with preserved ejection fraction
by: Martin Berger, et al.
Published: (2024-12-01)

Prediction model of rehospitalization and mortality in heart failure patients with preserved and mildly reduced ejection fraction: the AD2NNER risk score
by: Flavia-Mihaela Stoiculescu, et al.
Published: (2025-07-01)

Combination therapy of midodrine and droxidopa for refractory hypotension in heart failure with preserved ejection fraction per a pharmacist’s proposal: a case report
by: Yuki Asai, et al.
Published: (2021-03-01)

Gender‐specific risks for incident cancer in patients with different heart failure phenotypes
by: Qin‐Fen Chen, et al.
Published: (2025-02-01)

Incidence, determinants, and outcomes of recovered left ventricular ejection fraction (LVEF) in patients with non-ischemic systolic heart failure; a hospital-based cohort study
by: Prakash Chand Negi, et al.
Published: (2023-03-01)

Real world experience in effect of torsemide vs. furosemide after discharge in patients with HFpEF
by: Xiao Li, et al.
Published: (2025-02-01)

Characterizing Heart Failure Across the Spectrum of the Preserved Ejection Fraction: Does Heart Failure With Supranormal Ejection Fraction Exist? Data From the Swedish Heart Failure Registry
by: Laura Landucci, et al.
Published: (2025-03-01)

Biomarkers in the Pathogenesis of Heart Failure with Preserved as Well as Reduced Ejection Fraction: A Cross-sectional Study
by: Sowmiya Thiyagarajan, et al.
Published: (2025-06-01)

Metabolomics and a Breath Sensor Identify Acetone as a Biomarker for Heart Failure
by: Patrick A. Gladding, et al.
Published: (2022-12-01)

Tetranectin as a potential biomarker in heart failure with ejection fraction >45%: A prospective cohort study
by: Vulciu Paula Alexandra, et al.
Published: (2025-07-01)

Characteristics, outcomes and the necessity of continued guideline-directed medical therapy in patients with heart failure with improved ejection fraction
by: Qin-Fen Chen, et al.
Published: (2025-12-01)

Left atrioventricular coupling index measured by echocardiography in heart failure with preserved ejection fraction
by: Hai Nguyen Ngoc Dang, et al.
Published: (2025-07-01)

Insulin Resistance Is Associated With Heart Failure With Recovered Ejection Fraction in Patients Without Diabetes
by: Chen Die Yang, et al.
Published: (2022-10-01)

Total 25-Hydroxyvitamin D Is an Independent Marker of Left Ventricular Ejection Fraction in Heart Failure with Reduced and Mildly Reduced Ejection Fraction
by: Timea Magdolna Szabo, et al.
Published: (2023-10-01)

Cost-utility analysis of empagliflozin in heart failure patients with reduced and preserved ejection fraction in China
by: Yi Tang, et al.
Published: (2022-10-01)

Sirt1 Activity in PBMCs as a Biomarker of Different Heart Failure Phenotypes
by: Valeria Conti, et al.
Published: (2020-11-01)

Correlation of β-adrenergic reactivity of erythrocyte membranes with clinical characteristics of patients with coronary artery disease and HF with preserved and reduced ejection fraction
by: E. F. Muslimova, et al.
Published: (2025-01-01)

Circulating Cell-Free Nuclear DNA Predicted an Improvement of Systolic Left Ventricular Function in Individuals with Chronic Heart Failure with Reduced Ejection Fraction
by: Tetiana Berezina, et al.
Published: (2024-10-01)

Associations of short‐ and long‐term mortality with admission blood pressure in Chinese patients with different heart failure subtypes
by: Shilan Chen, et al.
Published: (2022-12-01)

The Impact of Specialised Heart Failure Outpatient Care on the Long-Term Application of Guideline-Directed Medical Therapy and on Prognosis in Heart Failure with Reduced Ejection Fraction
by: Balázs Muk, et al.
Published: (2024-01-01)

Uric Acid Predicts Recovery of Left Ventricular Function and Adverse Events in Heart Failure With Reduced Ejection Fraction: Potential Mechanistic Insight From Network Analyses
by: Xiqiang Wang, et al.
Published: (2022-07-01)

Predictors and Prognostic Factors of Heart Failure with Improved Ejection Fraction
by: Nilian Wu, et al.
Published: (2024-08-01)

Prediabetes and insulin resistance in a population of patients with heart failure and reduced or preserved ejection fraction but without diabetes, overweight or hypertension
by: Tran Kim Son, et al.
Published: (2022-05-01)

Effects of different sodium–glucose cotransporter 2 inhibitors in heart failure with reduced or preserved ejection fraction: a network meta-analysis
by: Xiaohua Lan, et al.
Published: (2024-05-01)